NeoGenomics (NASDAQ:NEO) Earns Neutral Rating from Analysts at Guggenheim
Guggenheim initiated coverage on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a research report released on Thursday, Marketbeat Ratings reports. The firm issued a neutral rating on the medical research company’s stock. A number of other brokerages have also recently issued reports on NEO. Bank of America dropped their price objective on NeoGenomics from […]
Guggenheim initiated coverage on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a research report released on Thursday, Marketbeat Ratings reports. The firm issued a neutral rating on the medical research company’s stock. A number of other brokerages have also recently issued reports on NEO. Bank of America dropped their price objective on NeoGenomics from […]
